Extended Spectrum β-lactamase–producing <italic>E. coli</italic>-related Nosocomial Peritonitis Treated Successfully with Meropenem in a Patient on Peritoneal Dialysis
Author(s) -
Seong Kyu Jeong,
Yeong Hee Ham,
Jin Hyuk Jo,
Yeong Sin Sin,
Dong Won Heo,
Hark Rım
Publication year - 2013
Publication title -
kosin medical journal
Language(s) - English
Resource type - Journals
eISSN - 2586-7024
pISSN - 2005-9531
DOI - 10.7180/kmj.2013.28.1.43
Subject(s) - medicine , peritonitis , peritoneal dialysis , meropenem , staphylococcus epidermidis , continuous ambulatory peritoneal dialysis , carbapenem , antibiotics , surgery , gastroenterology , staphylococcus aureus , microbiology and biotechnology , antibiotic resistance , biology , genetics , bacteria
Peritonitis is a common and potentially serious infection in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). The most common organisms usually associated with CAPD peritonitis are Staphylococcus aureus and Staphylococcus epidermidis. Rarely, aerobic gram negative bacilli have been the causative agents of CAPD peritonitis. The treatment of CAPD peritonitis requires removal of the peritoneal catheter and treatment with parenteral antibiotics active against the causative pathogen. While hospitalized for CAPD peritonitis, a 55-year-old man on CAPD had nosocomial peritonitis secondary to infection by ESBL–producing E.coli, that was sensitive to imipenem and meropenem. He was treated successfully with a 4-week course of intraperitoneal meropenem therapy without subsequent relapse, loss of peritoneal catheter, ultrafiltration failure, or dialysis inadequacy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom